Core Insights - Sotera Health Company reported revenue of $290.2 million for the quarter ended December 2024, a decrease of 6.5% compared to the same period last year [1] - The earnings per share (EPS) for the quarter was $0.21, down from $0.26 in the year-ago quarter, aligning with the consensus EPS estimate [1] - The reported revenue fell short of the Zacks Consensus Estimate of $291.56 million, resulting in a surprise of -0.46% [1] Financial Performance - Net Revenues for Sterigenics were reported at $179.43 million, slightly below the estimated $182.82 million, but showed a year-over-year increase of 4.2% [4] - Nelson Labs reported Net Revenues of $53.98 million, which was lower than the estimated $55.49 million, reflecting a year-over-year decline of 7.3% [4] - Nordion's Net Revenues were $56.79 million, exceeding the average estimate of $53.25 million, but represented a significant year-over-year decrease of 28.9% [4] Segment Income - Segment Income for Sterigenics was $99.59 million, slightly below the average estimate of $101.07 million [4] - Nelson Labs achieved Segment Income of $18.07 million, which was above the average estimate of $17.87 million [4] - Nordion's Segment Income was reported at $35.28 million, surpassing the average estimate of $33.55 million [4] Stock Performance - Shares of Sotera Health have returned -0.3% over the past month, compared to a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Sotera Health Company (SHC) reported quarterly earnings of $0.21 per share, matching the Zacks Consensus Estimate, but down from $0.26 per share a year ago [1] - The company posted revenues of $290.2 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.46% and down from $310.24 million year-over-year [2] - The stock has underperformed the market, losing about 0.3% since the beginning of the year compared to the S&P 500's gain of 1.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.14 on revenues of $262.37 million, and for the current fiscal year, it is $0.78 on revenues of $1.15 billion [7] - The estimate revisions trend for Sotera Health is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical Services industry, to which Sotera Health belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]

Revenue Results - Sotera Health Company announced preliminary revenue results for full-year 2024, which are within the guidance provided during the third quarter earnings release[6] - The revenue results are subject to completion of year-end financial closing procedures and audit by the independent registered public accounting firm[7] Business Update - Michael B. Petras, Jr., Chairman and CEO, will deliver a business update at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025[8]

Core Insights - Sotera Health Company reported a decrease in net revenues for the fourth quarter of 2024, down 6.5% to $290 million compared to $310 million in the same period of 2023, with a net income of $12 million or $0.04 per diluted share [2][3] - For the full year 2024, net revenues increased by 4.9% to $1.10 billion, with net income of $44 million or $0.16 per diluted share, marking the 19th consecutive year of revenue growth for the company [3][4] - The company anticipates a revenue growth outlook for 2025 in the range of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%, both on a constant currency basis [9][18] Financial Performance - Fourth-quarter 2024 adjusted EBITDA decreased by 8.3% to $153 million, with adjusted earnings per diluted share of $0.21, a decrease of $0.02 from the previous year [2][3] - Full-year 2024 adjusted EBITDA increased by 3.9% to $549 million, with adjusted EPS of $0.70, down $0.02 from 2023 [3][9] - The company had total debt of $2.3 billion and cash and cash equivalents of $277 million as of December 31, 2024, with a net leverage ratio of 3.7x [16][46] Business Segment Performance - In the fourth quarter of 2024, Sterigenics reported net revenues of $179 million, an increase of 4.2% year-over-year, while Nordion's revenues decreased by 28.9% to $57 million due to cobalt harvest timing [5][10] - For full-year 2024, Sterigenics net revenues were $698 million, up 4.6%, and Nordion's revenues increased by 8.0% to $173 million [6][11] - Nelson Labs experienced a revenue decline of 7.3% in the fourth quarter, but for the full year, revenues increased by 3.4% to $229 million [13][14] Governance and Strategic Developments - The company appointed Chris Simon, CEO of Haemonetics, to its board and named Vince Petrella as lead independent director, enhancing its governance structure [4] - The company continues to focus on customer satisfaction, achieving scores over 80%, and has expanded its Sterigenics facility [4]

Core Viewpoint - Sotera Health Company reported a decline in net revenues for the fourth quarter of 2024, while achieving overall revenue growth for the full year, marking the 19th consecutive year of annual revenue growth [4][8]. Financial Performance - Fourth-quarter 2024 net revenues decreased by 6.5% to $290 million compared to $310 million in the same period of 2023, with a constant currency decrease of 5.2% [2]. - Full-year 2024 net revenues increased by 4.9% to $1.10 billion, up from $1.05 billion in 2023, with a constant currency increase of 5.4% [3][8]. - Fourth-quarter net income was $12 million, or $0.04 per diluted share, down from $39 million, or $0.14 per diluted share in the fourth quarter of 2023 [2]. - Full-year net income was $44 million, or $0.16 per diluted share, compared to $51 million, or $0.18 per diluted share in 2023 [3][8]. - Adjusted EBITDA for the fourth quarter decreased by 8.3% to $153 million, while for the full year, it increased by 3.9% to $549 million [2][3]. Business Segment Performance - Sterigenics segment revenues for the fourth quarter were $179 million, an increase of 4.2% year-over-year, with segment income rising by 5.1% to $100 million [5][6]. - Nordion segment revenues for the fourth quarter decreased by 28.9% to $57 million, primarily due to cobalt harvest schedule timing, with segment income down 33.8% to $35 million [9][11]. - Nelson Labs segment revenues for the fourth quarter were $54 million, a decrease of 7.3%, with segment income decreasing by 3.3% to $18 million [12][14]. Balance Sheet and Liquidity - As of December 31, 2024, Sotera Health had total debt of $2.3 billion and cash and cash equivalents of $277 million, compared to $2.3 billion in debt and $296 million in cash at the end of 2023 [15]. - The company's Net Leverage Ratio as of December 31, 2024, was 3.7x, down from 3.8x at the end of 2023 [15][46]. 2025 Outlook - The company anticipates net revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5% for the full year 2025, both on a constant currency basis [8][17].

Core Insights - Wall Street analysts expect Sotera Health Company (SHC) to report quarterly earnings of $0.21 per share, reflecting a year-over-year decline of 19.2% [1] - Revenues are projected to be $290.59 million, down 6.3% from the same quarter last year [1] - There has been no revision in the consensus EPS estimate over the past 30 days, indicating stability in analysts' projections [1] Earnings Estimates - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock [2] - Empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [2] Key Metrics Analysis - Analysts predict 'Net Revenues- Sterigenics' at $182.82 million, indicating a change of +6.2% from the prior-year quarter [4] - 'Net Revenues- Nelson Labs' is expected to reach $55.49 million, reflecting a decline of 4.7% from the previous year [4] - 'Net Revenues- Nordion' is estimated at $53.25 million, showing a significant decrease of 33.3% from the prior-year quarter [4] Segment Income Projections - 'Segment Income- Sterigenics' is projected to be $101.07 million, up from $94.75 million in the same quarter last year [5] - 'Segment Income- Nelson Labs' is expected to reach $17.87 million, down from $18.68 million in the previous year [5] - 'Segment Income- Nordion' is estimated at $33.55 million, compared to $53.32 million a year ago [6] Stock Performance - Shares of Sotera Health have shown a return of -1% over the past month, compared to a -0.5% change in the Zacks S&P 500 composite [6] - With a Zacks Rank 4 (Sell), SHC is anticipated to underperform the overall market in the near future [6]

Core Viewpoint - Sotera Health Company is set to release its financial results for the fourth quarter and full year ended December 31, 2024, on February 27, 2025, before market opening, followed by a conference call to discuss the results [1]. Company Overview - Sotera Health Company is a leading global provider of end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, operating through three businesses: Sterigenics®, Nordion®, and Nelson Labs® [4]. Financial Results Announcement - The financial results will be released before the market opens on February 27, 2025, and a conference call will be held at 9:00 a.m. Eastern Time to discuss the operating highlights and financial results [1]. - Participants can join the live call by dialing specific numbers based on their location, and a live webcast will also be available [2]. Investor Relations - Updates relevant to investors can be found on the Investor Relations section of the company's website, including developments related to Ethylene Oxide [3].

Core Viewpoint - Sotera Health Company reported a strong performance in 2024, with expected revenues of approximately $1.1 billion, reflecting nearly 5% growth compared to 2023, indicating the resilience of its business model in various market conditions [2]. Company Overview - Sotera Health is a leading global provider of end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, operating through three main businesses: Sterigenics, Nordion, and Nelson Labs [6]. Financial Performance - The company anticipates full-year revenues of around $1.1 billion for 2024, which represents a growth of nearly 5% from 2023 and more than 5% growth on a constant currency basis [2]. - The financial results for the three months and year ended December 31, 2024, are still being finalized, and the actual results may vary from preliminary estimates [5]. Investor Engagement - The Chairman and CEO, Michael B. Petras, Jr., along with other executives, is participating in investor meetings at the 43rd Annual J.P. Morgan Healthcare Conference, with a live webcast of the presentation available on the company's website [2].

CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:15 a.m. Eastern Time. Mr. Petras, Jon Lyons, Senior Vice President and CFO, and Jason Pet ...

CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Com ...